{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ruicci KM"],"funding":["NCI NIH HHS","Canadian Institutes of Health Research","CIHR"],"pagination":["217"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7559997"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(1)"],"pubmed_abstract":["Background
Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) pathway is common in many malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite pre-clinical and clinical studies, outcomes from targeting the PI3K pathway have been underwhelming and the development of drug resistance poses a significant barrier to patient treatment. In the present study, we examined mechanisms of acquired resistance to the PI3Kα inhibitor alpelisib (formerly BYL719) in HNSCC cell lines and patient-derived xenografts (PDXs).Methods
Five unique PDX mouse models and three HNSCC cell lines were used. All cell lines and xenografts underwent genomic characterization prior to study. Serial drug treatment was conducted in vitro and in vivo to develop multiple, clin"],"journal":["Journal of experimental & clinical cancer research : CR"],"pubmed_title":["TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma."],"pmcid":["PMC7559997"],"funding_grant_id":["P50 CA211015","340674"],"pubmed_authors":["Meens J","Fung K","Ailles L","MacNeil D","Ruicci KM","Mymryk JS","Stecho W","Howlett CJ","Nichols AC","Boutros PC","Yoo J","Plantinga P","Pinto N","Barrett JW"],"additional_accession":[]},"is_claimable":false,"name":"TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.","description":"Background
Aberrant activation of the phosphatidylinositol 3-kinase (PI3K) pathway is common in many malignancies, including head and neck squamous cell carcinoma (HNSCC). Despite pre-clinical and clinical studies, outcomes from targeting the PI3K pathway have been underwhelming and the development of drug resistance poses a significant barrier to patient treatment. In the present study, we examined mechanisms of acquired resistance to the PI3Kα inhibitor alpelisib (formerly BYL719) in HNSCC cell lines and patient-derived xenografts (PDXs).Methods
Five unique PDX mouse models and three HNSCC cell lines were used. All cell lines and xenografts underwent genomic characterization prior to study. Serial drug treatment was conducted in vitro and in vivo to develop multiple, clin","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2026-07-14T14:38:37.56Z","creation":"2020-10-29T12:35:45Z"},"accession":"S-EPMC7559997","cross_references":{"pubmed":["33059733"],"doi":["10.1186/s13046-020-01713-9"]}}